Accuray Incorporated (ARAY)
$2.26
Rating:
Recommendation:
Buy
| Symbol | ARAY |
|---|---|
| Price | $2.26 |
| Beta | 1.916 |
| Volume Avg. | 0.70M |
| Market Cap | 209.733M |
| Shares () | - |
| 52 Week Range | 2.08-5.93 |
| 1y Target Est | - |
| DCF Unlevered | ARAY DCF -> | |
|---|---|---|
| DCF Levered | ARAY LDCF -> | |
| ROE | -23.92% | Sell |
| ROA | -2.77% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 809.60% | Strong Buy |
| P/E | - | |
| P/B | 4.02 | Strong Buy |
Latest ARAY news
About
Download (Excel)Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.